199 related articles for article (PubMed ID: 16719778)
21. New non-symmetrical choline kinase inhibitors.
Schiaffino-Ortega S; López-Cara LC; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Espinosa A; Marco C; Entrena A
Bioorg Med Chem; 2013 Nov; 21(22):7146-54. PubMed ID: 24080101
[TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling.
Yalcin A; Clem B; Makoni S; Clem A; Nelson K; Thornburg J; Siow D; Lane AN; Brock SE; Goswami U; Eaton JW; Telang S; Chesney J
Oncogene; 2010 Jan; 29(1):139-49. PubMed ID: 19855431
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells.
Nimmagadda S; Glunde K; Pomper MG; Bhujwalla ZM
Neoplasia; 2009 May; 11(5):477-84. PubMed ID: 19412432
[TBL] [Abstract][Full Text] [Related]
24. Modulation of choline kinase activity in human cancer cells observed by dynamic 31P NMR.
Gabellieri C; Beloueche-Babari M; Jamin Y; Payne GS; Leach MO; Eykyn TR
NMR Biomed; 2009 May; 22(4):456-61. PubMed ID: 19156696
[TBL] [Abstract][Full Text] [Related]
25. Choline Kinase: An Unexpected Journey for a Precision Medicine Strategy in Human Diseases.
Lacal JC; Zimmerman T; Campos JM
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34070409
[TBL] [Abstract][Full Text] [Related]
26. Choline kinase alpha depletion selectively kills tumoral cells.
Bañez-Coronel M; Ramírez de Molina A; Rodríguez-González A; Sarmentero J; Ramos MA; García-Cabezas MA; García-Oroz L; Lacal JC
Curr Cancer Drug Targets; 2008 Dec; 8(8):709-19. PubMed ID: 19075594
[TBL] [Abstract][Full Text] [Related]
27. Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions.
Gallego-Ortega D; Gómez del Pulgar T; Valdés-Mora F; Cebrián A; Lacal JC
Adv Enzyme Regul; 2011; 51(1):183-94. PubMed ID: 21035492
[TBL] [Abstract][Full Text] [Related]
28. Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy.
Gruber J; See Too WC; Wong MT; Lavie A; McSorley T; Konrad M
FEBS J; 2012 Jun; 279(11):1915-28. PubMed ID: 22429312
[TBL] [Abstract][Full Text] [Related]
29. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy.
Ramírez de Molina A; Gallego-Ortega D; Sarmentero-Estrada J; Lagares D; Gómez Del Pulgar T; Bandrés E; García-Foncillas J; Lacal JC
Int J Biochem Cell Biol; 2008; 40(9):1753-63. PubMed ID: 18296102
[TBL] [Abstract][Full Text] [Related]
30. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells.
Li M; Peng Z; Liu Q; Sun J; Yao S; Liu Q
Oncol Rep; 2013 Jan; 29(1):205-11. PubMed ID: 23124523
[TBL] [Abstract][Full Text] [Related]
31. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the design of choline kinase α inhibitors and the molecular basis of their inhibition.
Rubio-Ruiz B; Serrán-Aguilera L; Hurtado-Guerrero R; Conejo-García A
Med Res Rev; 2021 Mar; 41(2):902-927. PubMed ID: 33103259
[TBL] [Abstract][Full Text] [Related]
33. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.
Ramírez de Molina A; Rodríguez-González A; Gutiérrez R; Martínez-Piñeiro L; Sánchez J; Bonilla F; Rosell R; Lacal J
Biochem Biophys Res Commun; 2002 Aug; 296(3):580-3. PubMed ID: 12176020
[TBL] [Abstract][Full Text] [Related]
35. Anticancer bisquaternary heterocyclic compounds: a ras-ional design.
Campos J; Núñez C; Díaz JJ; Sánchez RM; Gallo MA; Espinosa A
Farmaco; 2003 Mar; 58(3):221-9. PubMed ID: 12620418
[TBL] [Abstract][Full Text] [Related]
36. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.
Ramírez de Molina A; Gallego-Ortega D; Sarmentero J; Bañez-Coronel M; Martín-Cantalejo Y; Lacal JC
Cancer Res; 2005 Jul; 65(13):5647-53. PubMed ID: 15994937
[TBL] [Abstract][Full Text] [Related]
37. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
Hernández-Alcoceba R; Fernández F; Lacal JC
Cancer Res; 1999 Jul; 59(13):3112-8. PubMed ID: 10397253
[TBL] [Abstract][Full Text] [Related]
38. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
39. (Q)SAR studies to design new human choline kinase inhibitors as antiproliferative drugs.
Campos JM; Sánchez-Martín RM; Conejo-García A; Entrena A; Gallo MA; Espinosa A
Curr Med Chem; 2006; 13(11):1231-48. PubMed ID: 16712467
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of choline kinase renders a highly selective cytotoxic effect in tumour cells through a mitochondrial independent mechanism.
Rodríguez-González A; Ramírez de Molina A; Bañez-Coronel M; Megias D; Lacal JC
Int J Oncol; 2005 Apr; 26(4):999-1008. PubMed ID: 15753995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
